Overview

MRI Study With Ferumoxytol in Assessing Early Response in Patients With Glioblastoma Multiforme Receiving Temozolomide and Radiation Therapy

Status:
Completed

Trial end date:
2014-06-01

Target enrollment:

Participant gender:

Summary

This pilot clinical trial studies how a magnetic resonance imaging (MRI) study with ferumoxytol works as a contrasting agent in assessing early response in patients with glioblastoma multiforme receiving temozolomide and radiation therapy. Ferumoxytol is a very small form of iron particles that are injected into the body and taken up by certain tissues which may make these tissues easier to see during imaging. Diagnostic procedures, such as an MRI study with ferumoxytol, may help measure a patient's response to earlier treatment.

Phase:

N/A

Details

Lead Sponsor:

OHSU Knight Cancer Institute

Collaborator:

National Cancer Institute (NCI)

Treatments:

Ferrosoferric Oxide
Temozolomide